Skip to content


  • Poster presentation
  • Open Access

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data

  • 1,
  • 2,
  • 3 and
  • 1
Journal for ImmunoTherapy of Cancer20153 (Suppl 1) :P7

  • Published:


  • Breast Cancer
  • Estrogen Receptor
  • Breast Cancer Patient
  • Mesenchymal Transition
  • Gene Expression Signature

PD-L1 is a ligand that upon binding to its receptor (PD-1) on T-cells leads to T-cell anergy/and or apoptosis [1, 2]. We have shown that PD-L1 is expressed in breast cancer where its expression correlates with estrogen receptor (ER) negativity [3]. To understand the mechanism of the constitutive expression of PD-L1 in tumor cells of ER negative cells we used gene-in and out approach, large scale bioinformatics and immunohistochemistry. We have demonstrated that epithelial to mesenchymal transition (EMT) upregulates PD-L1 expression while cells expressing ER downregulates PD-L1, in parallel with reversal of EMT process. Bioinformatics analysis of gene expression signatures of breast tumors showed a significant correlation between EMT score and PD-L1 mRNA expression. Strikingly, very strong association were found between PD-L1 expression and claudin low breast cancer, a subset of breast cancer known to have high EMT score. In conclusion, we have characterized the expression of PD-L1 in breast cancer and we have demonstrated a strong association between PD-L1 expression, EMT status and claudin-Low breast cancer. Our finding will be essential for choosing the appropriate subset of breast cancer patients that will likely benefit from anti-PD-L1 targeted therapy and understand biological changes upon anti-PD-L1 therapy.

Authors’ Affiliations

Stem Cell & Tissue Re-engineering Program, King Faisal Specialist Hospital and & Research Centre, Takhassusi Road, Al-Maathar, Riyadh, Saudi Arabia
Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital & Research, Takhassusi Road, Al-Maathar, Riyadh, Saudi Arab
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arab


  1. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000, 192 (7): 1027-1034. 10.1084/jem.192.7.1027.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, Korthauer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, et al: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol. 2003, 170 (7): 3637-3644. 10.4049/jimmunol.170.7.3637.View ArticlePubMedGoogle Scholar
  3. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Amer Bin S, Tulbah A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006, 8 (3): 190-198. 10.1593/neo.05733.PubMed CentralView ArticlePubMedGoogle Scholar